Progressing from primary care to early diagnosis in AD has advanced significantly through referral for screening and analysis of Aβ and tau biomarkers in brain, CSF and blood samples increasing the probability of early diagnosis and inclusion in therapeutic trials [10–14]. Here, MAPT is linked to Alzheimer disease.